A Health Impact Assessment of CRISPR-Cas9 as a Therapeutic Approach for Prader-Willi Syndrome
DOI:
https://doi.org/10.36877/pddbs.a0000592Abstract
Prader-Willi Syndrome is a rare neurodevelopmental genetic disorder resulting from expression defects of the exclusively paternally-expressed PWS locus at chromosome 15q11-q13. Even though its multifaceted manifestations and potentially fatal comorbidities poses universal concern, it remains incurable. Thus, this commentary applies a health impact assessment framework to evaluate the potential behind CRISPR-Cas9 gene-editing technology as a therapeutic intervention for PWS. While this novel technique displays outstanding precision and effectiveness in the targeted identification and demethylation of the silenced maternal locus, challenges such as off-target mutations, safety, and ethical implications warrant additional improvements. Therefore, recommendations regarding future research and clinical implementation are also proposed.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rachel Xue-Yu Teoh, Nancy Choon-Si Ng, Rebecca Shin-Yee Wong
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:
Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.
This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes.
The author(s) permits HH Publisher to publish this article that has not been submitted elsewhere.
